阿帕替尼联合GP方案二线及以上治疗晚期复发三阴性乳腺癌的疗效分析(1)
【摘要】 目的 分析阿帕替尼聯合吉西他滨联合顺铂(GP)方案二线及以上治疗晚期复发三阴性乳腺癌(TNBC)的疗效。方法 46例晚期复发三阴性乳腺癌患者， 按照治疗方案不同分为对照组与观察组， 各23例。对照组给予GP方案化疗， 观察组给予GP方案联合阿帕替尼治疗。比较两组患者近期临床疗效、无进展生存期(PFS)及不良反应发生情况。结果 对照组患者的客观缓解率(ORR)和疾病控制率(DCR)分别为30.4%和60.9%， 观察组患者的ORR和DCR分别为60.9%和87.0%， 观察组患者的ORR及DCR均高于对照组， 差异均具有统计学意义(P<0.05)。两组患者的随访时间为3～13个月， 对照组无进展生存期为(4.3±1.5)个月， 观察组患者的无进展生存期为(7.9±1.8)个月， 观察组患者的无进展生存期显著长于对照组， 差异具有统计学意义(P<0.05)。观察组患者的高血压、手足综合征、乏力、消化道反应、出血发生率分别为73.9%、56.5%、73.9%、82.6%、21.7%， 均高于对照组的4.3%、8.7%、39.1%、43.5%、0， 差异均具有统计学意义(P<0.05)。结论 阿帕替尼联合GP方案二线及以上治疗晚期复发三阴性乳腺癌患者， 可显著提高ORR及DCR， 且对乳腺癌脑转移显示较好的疗效;不良反应可耐受， 安全性好。
【关键词】 阿帕替尼;晚期复发三阴性乳腺癌;吉西他滨联合顺铂方案;客观缓解率;疾病控制率
【Abstract】 Objective To analyze the efficacy of apatinib combined with gemcitabine and cisplatin (GP) regimen in the treatment of advanced recurrent triple negative breast cancer (TNBC) after failure of second-line or beyond treatment. Methods A total of 46 patients with advanced recurrent triple negative breast cancer were divided into control group and observation group by different treatment regimens， with 23 cases in each group. The control group received GP regimen for chemotherapy， and the observation group received apatinib combined with GP regimen. The short-term clinical efficacy， progression free survival (PFS) and occurrence of adverse reactions were compared between the two groups. Results The objective response rate (ORR) and disease control rate (DCR) were 30.4% and 60.9% respectively in the control group， which were 60.9% and 87.0% in the observation group. The ORR and DCR in the observation group was higher than those in the control group， and the difference was statistically significant (P<0.05). The follow-up time of patients in the two groups was 3-13 months. The progression free survival time of the control group was (4.3±1.5) months， and the progression free survival time of the observation group was (7.9±1.8) months. The progression free survival time of the observation group was significantly longer than that of the control group， and the difference was statistically significant (P<0.05). The incidence of hypertension， hand and foot syndrome， asthenia， gastrointestinal reaction and hemorrhage were 73.9%， 56.5%， 73.9%， 82.6% and 21.7% respectively in the observation group， which were higher than 4.3%， 8.7%， 39.1%， 43.5% and 0 in the control group， and their difference was statistically significant (P<0.05). Conclusion For patients with advanced recurrent triple negative breast cancer after failure of second-line or beyond treatment， apatinib combined with GP regimen can significantly improve ORR and DCR， and show a good effect on brain metastasis of breast cancer with tolerable adverse reactions and high safety., http://www.100md.com(黄芳)
【关键词】 阿帕替尼;晚期复发三阴性乳腺癌;吉西他滨联合顺铂方案;客观缓解率;疾病控制率
【Abstract】 Objective To analyze the efficacy of apatinib combined with gemcitabine and cisplatin (GP) regimen in the treatment of advanced recurrent triple negative breast cancer (TNBC) after failure of second-line or beyond treatment. Methods A total of 46 patients with advanced recurrent triple negative breast cancer were divided into control group and observation group by different treatment regimens， with 23 cases in each group. The control group received GP regimen for chemotherapy， and the observation group received apatinib combined with GP regimen. The short-term clinical efficacy， progression free survival (PFS) and occurrence of adverse reactions were compared between the two groups. Results The objective response rate (ORR) and disease control rate (DCR) were 30.4% and 60.9% respectively in the control group， which were 60.9% and 87.0% in the observation group. The ORR and DCR in the observation group was higher than those in the control group， and the difference was statistically significant (P<0.05). The follow-up time of patients in the two groups was 3-13 months. The progression free survival time of the control group was (4.3±1.5) months， and the progression free survival time of the observation group was (7.9±1.8) months. The progression free survival time of the observation group was significantly longer than that of the control group， and the difference was statistically significant (P<0.05). The incidence of hypertension， hand and foot syndrome， asthenia， gastrointestinal reaction and hemorrhage were 73.9%， 56.5%， 73.9%， 82.6% and 21.7% respectively in the observation group， which were higher than 4.3%， 8.7%， 39.1%， 43.5% and 0 in the control group， and their difference was statistically significant (P<0.05). Conclusion For patients with advanced recurrent triple negative breast cancer after failure of second-line or beyond treatment， apatinib combined with GP regimen can significantly improve ORR and DCR， and show a good effect on brain metastasis of breast cancer with tolerable adverse reactions and high safety., http://www.100md.com(黄芳)
参见：首页 > 医疗版 > 疾病专题 > 普通外科 > 乳腺癌